AI - PHARMACEUTICAL TECHNOLOGY
AI-PPT: Fusing Tradition with Cutting-Edge Science
AI-PPT, the next-generation evolution of Pharmaceutical Platform Technology (PPT®), combines the power of artificial intelligence with centuries-old natural medicine to optimize therapeutic compounds. This unique approach seamlessly blends traditional knowledge with modern pharmacology, making drug discovery both precise and efficient.
A Two-Stage Process Driven by Artificial Intelligence
At the heart of AI-PPT is a two-stage process that leverages artificial intelligence to drive discovery and development. In the first stage, AI computationally identifies active botanical compounds based on their pharmacokinetic (PK) and pharmacodynamic (PD) properties. Through advanced data mining and machine learning, we analyze large datasets to select the most promising ingredients with optimal absorption, distribution, metabolism, and excretion (ADME) profiles while minimizing toxicity.
In the second stage, these selected compounds undergo rigorous biological testing using cutting-edge molecular techniques. This includes the use of 3D organoid models—cell structures that mimic human organs—and -omics technologies to precisely assess efficacy and safety. By integrating AI with biological research, we can fast-track the development of effective therapies, moving from discovery to market with greater speed and accuracy.
Precision and Validation Through Analytical Technology
Throughout both stages, our use of advanced analytical technologies ensures the identity, purity, and potency of the active ingredients. This verification process guarantees that our formulations meet the highest standards of consistency, quality, and safety, further enhancing the reliability of AI-PPT in pharmaceutical development.
Products
Sinoveda has successfully brought multiple products to market based on its proprietary research.
Effecti-Cal®
Effecti-Cal is a patented new form of multi-element calcium product for the maintenance of bone health and reducing the risk of developing osteoporosis. Effecti-Cal is engineered to be more soluble in the intestine and provide more usable calcium per dose, compared to existing calcium products.
People who require a calcium supplement face two challenges:
- The constipating effects of calcium, especially for sedentary individuals.
- Converting the calcium they consume into calcium their body can absorb.
Effecti-Cal was designed to solve both of these issues. Many products on the market are made with calcium carbonate which is much more difficult for the body to absorb. Effecti-Cal’s formula, using calcium acetate, is designed to most effectively deliver the amount of calcium your body needs in the most absorbable form. This means that a far higher percentage of the calcium consumed is actually absorbed to help build strong bones and improve health.
Since zinc and magnesium are often depleted in patients with low calcium intake, Effecti-Cal is supplemented with additional zinc and magnesium to maintain stable levels in the body.
Proflexa®
Proflexa delivers the ingredients you need in exact doses for better and long-term relief of aches and pains. It’s all thanks to our Pharmaceutical Platform Technology (PPT).
Free yourself from muscle, joint, shoulder and body pain with our cream which quickly penetrates the skin and provides immediate treatment and a long-lasting pain relief solution. Proflexa heals you from inside to outside.
Proflexa is made up of natural ingredients; clove, camphor and other constituents are best to soothe sore and aching muscles, promote and improve blood circulation and relax tendons.
By using our proprietary scientific approach, Proflexa delivers clinically proven results, every time.
Cordyva™
Health Canada has approved the NPN (Natural Product Number) for Cordyva™ – Sinoveda’s proprietary cordyceps-based product – confirming that it meets Health Canada’s requirements for safety, effectiveness and quality. It is a patent pending product developed using AI-PPT.
Cordyva™ is currently licensed for sale in Hong Kong under the trade name AntiCo as a therapy for Long Covid and the resolution of persistent respiratory ailments.
Sinoveda plans to announce the commencement of trials and the recruitment of candidates with Long COVID later in the summer. With the receipt of the NPN for Cordyva, Sinoveda plans on initially releasing the product to market as early as September 2024.
The Natural Product Number NPN 80130819 issued to Sinoveda will be located on every product label distributed.
